HC Wainwright Increases ADMA Biologics (NASDAQ:ADMA) Price Target to $26.00

ADMA Biologics (NASDAQ:ADMA) had its price target upped by analysts at HC Wainwright from $18.00 to $26.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 14.94% from the stock’s previous close. HC Wainwright also issued estimates for ADMA Biologics’ Q4 2024 earnings at $0.19 EPS, FY2024 earnings at $0.55 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James boosted their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $21.25.

ADMA Biologics Trading Up 14.7 %

NASDAQ ADMA opened at $22.62 on Friday. ADMA Biologics has a one year low of $3.60 and a one year high of $23.52. The firm has a 50 day simple moving average of $18.12 and a 200-day simple moving average of $13.89. The firm has a market cap of $5.27 billion, a price-to-earnings ratio of 161.57 and a beta of 0.64. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.02) earnings per share. Equities research analysts anticipate that ADMA Biologics will post 0.49 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 466,900 shares of company stock valued at $8,224,121 in the last ninety days. Insiders own 3.70% of the company’s stock.

Institutional Trading of ADMA Biologics

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in ADMA Biologics during the 2nd quarter worth approximately $29,000. Hollencrest Capital Management acquired a new stake in shares of ADMA Biologics in the third quarter valued at approximately $30,000. EntryPoint Capital LLC purchased a new position in shares of ADMA Biologics during the first quarter worth approximately $31,000. CWM LLC increased its holdings in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 4,367 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in ADMA Biologics in the 2nd quarter valued at $93,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.